Availability of FLT3 inhibitors: how do we use them?

被引：32
作者：
Perl, Alexander E. [1 ]
机构：
[1] Univ Penn, Leukemia Program, Abramson Canc Ctr, Philadelphia, PA 19104 USA
来源：
BLOOD | 2019年 / 134卷 / 09期
关键词：
ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATION; CELL TRANSPLANTATION; PHASE-I; SORAFENIB; MUTATIONS; GILTERITINIB; CHEMOTHERAPY; DIFFERENTIATION; MULTICENTER;
D O I：
10.1182/blood.2019876821
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The natural history of FLT3-mutated AML is changing after the approval of midostaurin for frontline therapy and gilteritinib for relapsed or refractory patients. Recently reported, positive randomized trials of the drugs gilteritinib, quizartinib, and sorafenib predict even wider use of FLT3 inhibitors going forward. FLT3 inhibitors now emerge as an important, if not indispensable, part of therapy for a large subset of high-risk patients.
引用
收藏
页码：741 / 745
页数：5
相关论文
共 46 条
  • [1] Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission
    Brunner, Andrew M.
    Li, Shuli
    Fathi, Amir T.
    Wadleigh, Martha
    Ho, Vincent T.
    Collier, Kerry
    Connolly, Christine
    Ballen, Karen K.
    Cutler, Corey S.
    Dey, Bimalangshu R.
    El-Jawahri, Areej
    Nikiforow, Sarah
    McAfee, Steven L.
    Koreth, John
    Deangelo, Daniel J.
    Alyea, Edwin P.
    Antin, Joseph H.
    Spitzer, Thomas R.
    Stone, Richard M.
    Soiffer, Robert J.
    Chen, Yi-Bin
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2016, 175 (03) : 496 - 504
  • [2] Sorafenib As Maintenance Therapy Post Allogeneic Stem Cell Transplantation for FLT3-ITD Positive AML: Results from the Randomized, Double-Blind, Placebo-Controlled Multicentre Sormain Trial
    Burchert, Andreas
    Bug, Gesine
    Finke, Juergen
    Stelljes, Matthias
    Rollig, Christoph
    Waesch, Ralph
    Bornhaeuser, Martin
    Berg, Tobias
    Lang, Fabian
    Ehninger, Gerhard
    Serve, Hubert
    Zeiser, Robert
    Wagner, Eva-Maria
    Kroeger, Nicolaus
    Wolschke, Christine
    Schleuning, Michael
    Elmaagacli, Ahmet
    Goetze, Katharina S.
    Schmid, Christoph
    Jost, Edgar
    Wolf, Dominik
    Boehm, Alexandra
    Thiede, Christian
    Haferlach, Torsten
    Bethge, Wolfgang
    Harnisch, Susanne
    Wittenberg, Michael
    Rospleszcz, Susanne
    Neubauer, Andreas
    Brugger, Markus
    Strauch, Konstantin
    Schade-Brittinger, Carmen
    Metzelder, Stephan K.
    [J]. BLOOD, 2018, 132
  • [3] Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia
    Chen, Yi-Bin
    Li, Shuli
    Lane, Andrew A.
    Connolly, Christine
    Del Rio, Candice
    Valles, Betsy
    Curtis, Morgan
    Ballen, Karen
    Cutler, Corey
    Dey, Bimalangshu R.
    El-Jawahri, Areej
    Fathi, Amir T.
    Ho, Vincent T.
    Joyce, Amy
    McAfee, Steven
    Rudek, Michelle
    Rajkhowa, Trivikram
    Verselis, Sigitas
    Antin, Joseph H.
    Spitzer, Thomas R.
    Levis, Mark
    Soiffer, Robert
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (12) : 2042 - 2048
  • [4] Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
    Cheson, BD
    Bennett, JM
    Kopecky, KJ
    Büchner, T
    Willman, CL
    Estey, EH
    Schiffer, CA
    Döhner, H
    Tallman, MS
    Lister, TA
    LoCocco, F
    Willemze, R
    Biondi, A
    Hiddemann, W
    Larson, RA
    Löwenberg, B
    Sanz, MA
    Head, DR
    Ohno, R
    Bloomfield, CD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) : 4642 - 4649
  • [5] Cortes JE, 2016, J Clin Oncol, V34, P7008
  • [6] Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
    Cortes, Jorge
    Perl, Alexander E.
    Dohner, Hartmut
    Kantarjian, Hagop
    Martinelli, Giovanni
    Kovacsovics, Tibor
    Rousselot, Philippe
    Steffen, Bjorn
    Dombret, Herve
    Estey, Elihu
    Strickland, Stephen
    Altman, Jessica K.
    Baldus, Claudia D.
    Burnett, Alan
    Kramer, Alwin
    Russell, Nigel
    Shah, Neil P.
    Smith, Catherine C.
    Wang, Eunice S.
    Ifrah, Norbert
    Gammon, Guy
    Trone, Denise
    Lazzaretto, Deborah
    Levis, Mark
    [J]. LANCET ONCOLOGY, 2018, 19 (07) : 889 - 903
  • [7] Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
    Cortes, Jorge E.
    Khaled, Samer
    Martinelli, Giovanni
    Perl, Alexander E.
    Ganguly, Siddhartha
    Russell, Nigel
    Kraemer, Alwin
    Dombret, Herve
    Hogge, Donna
    Jonas, Brian A.
    Leung, Anskar Yu-Hung
    Mehta, Priyanka
    Montesinos, Pau
    Radsak, Markus
    Sica, Simona
    Arunachalam, Meena
    Holmes, Melissa
    Kobayashi, Ken
    Namuyinga, Ruth
    Ge, Nanxiang
    Yver, Antoine
    Zhang, Yufen
    Levis, Mark J.
    [J]. LANCET ONCOLOGY, 2019, 20 (07) : 984 - 997
  • [8] Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML
    Cortes, Jorge E.
    Tallman, Martin S.
    Schiller, Gary J.
    Trone, Denise
    Gammon, Guy
    Goldberg, Stuart L.
    Perl, Alexander E.
    Marie, Jean-Pierre
    Martinelli, Giovanni
    Kantarjian, Hagop M.
    Levis, Mark J.
    [J]. BLOOD, 2018, 132 (06) : 598 - 607
  • [9] Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Status
    Cortes, Jorge E.
    Kantarjian, Hagop
    Foran, James M.
    Ghirdaladze, Darejan
    Zodelava, Mamia
    Borthakur, Gautam
    Gammon, Guy
    Trone, Denise
    Armstrong, Robert C.
    James, Joyce
    Levis, Mark
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (29) : 3681 - +
  • [10] FLT3 inhibitor-induced neutrophilic dermatosis
    Fathi, Amir T.
    Le, Long
    Hasserjian, Robert P.
    Sadrzadeh, Hossein
    Levis, Mark
    Chen, Yi-Bin
    [J]. BLOOD, 2013, 122 (02) : 239 - 242
12345